JP2007500176A5 - - Google Patents

Download PDF

Info

Publication number
JP2007500176A5
JP2007500176A5 JP2006521656A JP2006521656A JP2007500176A5 JP 2007500176 A5 JP2007500176 A5 JP 2007500176A5 JP 2006521656 A JP2006521656 A JP 2006521656A JP 2006521656 A JP2006521656 A JP 2006521656A JP 2007500176 A5 JP2007500176 A5 JP 2007500176A5
Authority
JP
Japan
Prior art keywords
water
drug
pharmaceutical composition
soluble
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006521656A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007500176A (ja
Filing date
Publication date
Priority claimed from GBGB0317663.3A external-priority patent/GB0317663D0/en
Application filed filed Critical
Publication of JP2007500176A publication Critical patent/JP2007500176A/ja
Publication of JP2007500176A5 publication Critical patent/JP2007500176A5/ja
Pending legal-status Critical Current

Links

JP2006521656A 2003-07-29 2004-07-27 医薬組成物 Pending JP2007500176A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0317663.3A GB0317663D0 (en) 2003-07-29 2003-07-29 Pharmaceutical composition
PCT/GB2004/003241 WO2005011647A2 (en) 2003-07-29 2004-07-27 Pharmaceutical composition

Publications (2)

Publication Number Publication Date
JP2007500176A JP2007500176A (ja) 2007-01-11
JP2007500176A5 true JP2007500176A5 (enExample) 2007-08-16

Family

ID=27799353

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006521656A Pending JP2007500176A (ja) 2003-07-29 2004-07-27 医薬組成物

Country Status (5)

Country Link
US (1) US20070141141A1 (enExample)
EP (1) EP1651233A2 (enExample)
JP (1) JP2007500176A (enExample)
GB (1) GB0317663D0 (enExample)
WO (1) WO2005011647A2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008055966A1 (en) * 2006-11-09 2008-05-15 Abbott Gmbh & Co. Kg Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor
EP1920767A1 (en) * 2006-11-09 2008-05-14 Abbott GmbH & Co. KG Melt-processed imatinib dosage form
WO2009100176A2 (en) * 2008-02-07 2009-08-13 Abbott Laboratories Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor
US8133506B2 (en) * 2008-03-12 2012-03-13 Aptalis Pharmatech, Inc. Drug delivery systems comprising weakly basic drugs and organic acids
JP5382334B2 (ja) * 2008-09-19 2014-01-08 ブラザー工業株式会社 インクジェット記録用水性インクおよび水性インクセット
US20110142770A1 (en) * 2009-12-16 2011-06-16 Fletcher Robert B Sunscreen compositions incorporating methylcellulose as an spf and/or ppd booster and methods
JP4574742B1 (ja) * 2010-04-08 2010-11-04 有限会社ミールジャパン プロポリス組成物
JP2013535516A (ja) * 2010-08-17 2013-09-12 ルピン・リミテッド ドロネダロンの制御放出製剤
EP3233064A1 (en) 2014-12-19 2017-10-25 Synthon BV Pharmaceutical composition comprising gefifinib
WO2016193860A1 (en) 2015-06-04 2016-12-08 Pfizer Inc. Solid dosage forms of palbociclib
JP6585193B2 (ja) * 2015-12-28 2019-10-02 沢井製薬株式会社 ゲフィチニブ含有錠剤
US10449195B2 (en) 2016-03-29 2019-10-22 Shenzhen Pharmacin Co., Ltd. Pharmaceutical formulation of palbociclib and a preparation method thereof
WO2017223018A1 (en) * 2016-06-23 2017-12-28 Dow Global Technologies Llc Esterified cellulose ethers comprising trimellityl groups
TWI793141B (zh) 2017-07-11 2023-02-21 日商快力膠囊股份有限公司 腸溶性硬質膠囊
JP7366893B2 (ja) * 2018-06-22 2023-10-23 クオリカプス株式会社 腸溶性硬質カプセル
CN114306245A (zh) 2020-09-29 2022-04-12 深圳市药欣生物科技有限公司 无定形固体分散体的药物组合物及其制备方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3608063A (en) * 1969-08-15 1971-09-21 Gilbert S Banker Molecular drug entrapment process and compositions
US4178376A (en) * 1977-01-21 1979-12-11 Interx Research Corporation Method for inducing rapid therapeutically effective antimalarial levels of certain selected conventional antimalarials
US4344934A (en) * 1978-11-20 1982-08-17 American Home Products Corporation Therapeutic compositions with enhanced bioavailability
US4704284A (en) * 1982-08-12 1987-11-03 Pfizer Inc. Long-acting matrix tablet formulations
US5342625A (en) * 1988-09-16 1994-08-30 Sandoz Ltd. Pharmaceutical compositions comprising cyclosporins
AU661533B2 (en) * 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
GB9207988D0 (en) * 1992-04-10 1992-05-27 Smithkline Beecham Plc Topical composition
WO1994008599A1 (en) * 1992-10-14 1994-04-28 The Regents Of The University Of Colorado Ion-pairing of drugs for improved efficacy and delivery
CA2164344C (en) * 1993-08-30 2004-06-29 Stanley Lech Tablet coating based on a melt-spun mixture of a saccharide and a polymer
US5559158A (en) * 1993-10-01 1996-09-24 Abbott Laboratories Pharmaceutical composition
ATE159257T1 (de) * 1994-05-03 1997-11-15 Ciba Geigy Ag Pyrrolopyrimidinderivate mit antiproliferativer wirkung
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
ATE554750T1 (de) * 1997-03-05 2012-05-15 Sugen Inc Hydrophobe pharmazeutische wirkstoffe enthaltende zubereitungen
EP0901786B1 (en) * 1997-08-11 2007-06-13 Pfizer Products Inc. Solid pharmaceutical dispersions with enhanced bioavailability
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
DE19911509A1 (de) * 1999-03-15 2000-09-21 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US6287599B1 (en) * 2000-12-20 2001-09-11 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
NZ527585A (en) * 2001-02-15 2005-04-29 Tanabe Seiyaku Co Tablets quickly disintegrated in oral cavity
KR100397792B1 (ko) * 2001-06-28 2003-09-13 한국과학기술연구원 4-(페닐아미노)-[1,4]디옥사노[2,3-g]퀴나졸린 유도체 및그의 제조방법
GB0124455D0 (en) * 2001-10-11 2001-12-05 Pfizer Ltd Pharmaceutical formulations
KR20040086452A (ko) * 2002-02-26 2004-10-08 아스트라제네카 아베 항암 화합물 zd1839의 신규한 결정질 형태
RU2318518C2 (ru) * 2002-02-26 2008-03-10 Астразенека Аб Фармацевтическая композиция, обладающая антипролиферативным действием (варианты), способ ее получения и способы с ее использованием

Similar Documents

Publication Publication Date Title
JP2007500176A5 (enExample)
ES2731601T3 (es) Composiciones de dosificación oral de liberación retardada que contienen CDDO-Me amorfo
JP5837732B2 (ja) ピルフェニドンおよび薬学的に受容可能な賦形剤のカプセル処方物
CN103096881B (zh) 含有具有不愉快味道的药物的膜制剂
JP5671560B2 (ja) 固体投与形中のテトラサイクリン金属錯体
JP7602324B2 (ja) 重水素化ドンペリドン組成物、方法、及び調製
WO2011110939A2 (en) Pharmaceutical compositions of substituted benzhydrylpiperazines
BR112018001859B1 (pt) Comprimido, e, método para produzir um comprimido
JP2008533127A5 (enExample)
CN103833713B (zh) 硝克柳胺化合物晶iii型、其制法和其药物组合物与用途
JP2015531749A5 (enExample)
CN118161464A (zh) 含阿司匹林的药物制剂及其制备方法和应用
JP2008174511A (ja) 苦味マスク組成物
JP5805891B2 (ja) 5−ヒドロキシ−1h−イミダゾール−4−カルボキサミドを含有する錠剤
CN105434398B (zh) 一种雷贝拉唑肠溶微丸及其制备方法
JP2007504223A5 (enExample)
WO2024078507A1 (zh) 麦角甾醇在制备防治胃溃疡药物中的应用
CN104093400A (zh) 稳定的无定形雷特格韦钾盐预混料及其制备方法
JP2007504222A5 (enExample)
CN113924145A (zh) 痛风或高尿酸血症的治疗药
KR20160025075A (ko) 구강내 속붕해 필름 조성물 및 그 제조방법
CN104473895A (zh) 拉莫三嗪口腔崩解缓释片
WO2000043041A1 (fr) Compositions medicamenteuses presentant une meilleure absorption orale
RU2007101521A (ru) Моногидрат натриевой соли s-тенатопразола и его применение в качестве ингибитора протонного насоса
JP6903252B2 (ja) キサンチンオキシダーゼ阻害剤含有腸溶性製剤